HRP20200276T1 - Stimulatori sgc - Google Patents
Stimulatori sgc Download PDFInfo
- Publication number
- HRP20200276T1 HRP20200276T1 HRP20200276TT HRP20200276T HRP20200276T1 HR P20200276 T1 HRP20200276 T1 HR P20200276T1 HR P20200276T T HRP20200276T T HR P20200276TT HR P20200276 T HRP20200276 T HR P20200276T HR P20200276 T1 HRP20200276 T1 HR P20200276T1
- Authority
- HR
- Croatia
- Prior art keywords
- disease
- pulmonary
- hypertension
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 229940127296 soluble guanylate cyclase stimulator Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 49
- 208000035475 disorder Diseases 0.000 claims 25
- 201000010099 disease Diseases 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 21
- 208000002815 pulmonary hypertension Diseases 0.000 claims 13
- 206010019280 Heart failures Diseases 0.000 claims 9
- 206010016654 Fibrosis Diseases 0.000 claims 8
- 206010020772 Hypertension Diseases 0.000 claims 8
- 230000002685 pulmonary effect Effects 0.000 claims 7
- 208000001647 Renal Insufficiency Diseases 0.000 claims 6
- 238000009825 accumulation Methods 0.000 claims 6
- 208000020832 chronic kidney disease Diseases 0.000 claims 6
- 201000006370 kidney failure Diseases 0.000 claims 6
- 238000002054 transplantation Methods 0.000 claims 6
- 208000006029 Cardiomegaly Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 5
- 230000001684 chronic effect Effects 0.000 claims 5
- 230000004761 fibrosis Effects 0.000 claims 5
- 210000004185 liver Anatomy 0.000 claims 5
- 206010006482 Bronchospasm Diseases 0.000 claims 4
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims 4
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 4
- 206010020880 Hypertrophy Diseases 0.000 claims 4
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 4
- 201000001068 Prinzmetal angina Diseases 0.000 claims 4
- 206010067284 Pulmonary arteriopathy Diseases 0.000 claims 4
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims 4
- 230000007885 bronchoconstriction Effects 0.000 claims 4
- 230000000747 cardiac effect Effects 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- 208000004990 Cardiorenal syndrome Diseases 0.000 claims 3
- 102000008186 Collagen Human genes 0.000 claims 3
- 108010035532 Collagen Proteins 0.000 claims 3
- 206010011878 Deafness Diseases 0.000 claims 3
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 3
- 208000034189 Sclerosis Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 230000007882 cirrhosis Effects 0.000 claims 3
- 229920001436 collagen Polymers 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 208000016354 hearing loss disease Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 208000019423 liver disease Diseases 0.000 claims 3
- 208000030761 polycystic kidney disease Diseases 0.000 claims 3
- 230000000750 progressive effect Effects 0.000 claims 3
- 201000002793 renal fibrosis Diseases 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- 208000037816 tissue injury Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010058079 Anomalous pulmonary venous connection Diseases 0.000 claims 2
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010053567 Coagulopathies Diseases 0.000 claims 2
- 208000029147 Collagen-vascular disease Diseases 0.000 claims 2
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 2
- 206010052895 Coronary artery insufficiency Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 2
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010021133 Hypoventilation Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 2
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 208000008771 Lymphadenopathy Diseases 0.000 claims 2
- 206010025219 Lymphangioma Diseases 0.000 claims 2
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000011682 Mitral valve disease Diseases 0.000 claims 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010034487 Pericarditis constrictive Diseases 0.000 claims 2
- 206010063985 Phytosterolaemia Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 2
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims 2
- 206010037457 Pulmonary vasculitis Diseases 0.000 claims 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 claims 2
- 208000002227 Sitosterolemia Diseases 0.000 claims 2
- 208000007718 Stable Angina Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010071436 Systolic dysfunction Diseases 0.000 claims 2
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 2
- 208000007814 Unstable Angina Diseases 0.000 claims 2
- 208000009325 Variant Angina Pectoris Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 208000013228 adenopathy Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 206010002906 aortic stenosis Diseases 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 208000037849 arterial hypertension Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000015294 blood coagulation disease Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 230000009852 coagulant defect Effects 0.000 claims 2
- 208000028831 congenital heart disease Diseases 0.000 claims 2
- 208000018631 connective tissue disease Diseases 0.000 claims 2
- 208000000839 constrictive pericarditis Diseases 0.000 claims 2
- 230000008021 deposition Effects 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 230000008694 endothelial dysfunction Effects 0.000 claims 2
- 230000003511 endothelial effect Effects 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 210000004024 hepatic stellate cell Anatomy 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 208000018875 hypoxemia Diseases 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- 230000036961 partial effect Effects 0.000 claims 2
- 230000010412 perfusion Effects 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 208000007232 portal hypertension Diseases 0.000 claims 2
- 201000011461 pre-eclampsia Diseases 0.000 claims 2
- 230000036316 preload Effects 0.000 claims 2
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 2
- 210000001147 pulmonary artery Anatomy 0.000 claims 2
- 208000037813 pulmonary venous hypertension Diseases 0.000 claims 2
- 230000002829 reductive effect Effects 0.000 claims 2
- 208000015658 resistant hypertension Diseases 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000004409 schistosomiasis Diseases 0.000 claims 2
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- 210000004003 subcutaneous fat Anatomy 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000002537 thrombolytic effect Effects 0.000 claims 2
- 230000001732 thrombotic effect Effects 0.000 claims 2
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002153 Anal fissure Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 208000016583 Anus disease Diseases 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 208000004746 Atrophic Vaginitis Diseases 0.000 claims 1
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 claims 1
- 206010011953 Decreased activity Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 206010056340 Diabetic ulcer Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 208000004483 Dyspareunia Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 1
- 208000009531 Fissure in Ano Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000016621 Hearing disease Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010048865 Hypoacusis Diseases 0.000 claims 1
- 206010021518 Impaired gastric emptying Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 206010061340 Peripheral embolism Diseases 0.000 claims 1
- 206010034576 Peripheral ischaemia Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 239000003633 blood substitute Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010007625 cardiogenic shock Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 230000004087 circulation Effects 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 231100000895 deafness Toxicity 0.000 claims 1
- 230000003205 diastolic effect Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 210000005069 ears Anatomy 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000001288 gastroparesis Diseases 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000001286 intracranial vasospasm Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000004089 microcirculation Effects 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 230000003041 necroinflammatory effect Effects 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 230000009424 thromboembolic effect Effects 0.000 claims 1
- 230000002885 thrombogenetic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 210000002229 urogenital system Anatomy 0.000 claims 1
- 208000037820 vascular cognitive impairment Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Claims (21)
1. Spoj predstavljen sljedećom formulom ili njegova farmaceutski prihvatljiva sol:
[image]
2. Farmaceutski sastav koji sadrži spoj iz zahtjeva 1 ili njegovu farmaceutski prihvatljivu sol te jednu pomoćnu tvari ili više njih.
3. Spoj iz zahtjeva 1 ili njegova farmaceutski prihvatljiva sol, za upotrebu u liječenju bolesti, zdravstvenog stanja ili poremećaja odabranog među:
(1) perifernim, plućnim, jetrenim, bubrežnim, srčanim ili cerebralnim vaskularnim / endotelnim poremećajima/stanjima ili bolestima na drugi način povezanima s cirkulacijom i odabranima među:
• poremećajima povezanima s visokim krvnim tlakom i smanjenim protokom koronarne krvi; povišenim akutnim i kroničnim koronarnim krvnim tlakom; arterijskom hipertenzijom; vaskularnim poremećajem koji je posljedica srčanih i bubrežnih komplikacija, srčanih bolesti, moždanog udara, cerebralne ishemije ili zatajenja bubrega; rezistentnom hipertenzijom; dijabetičkom hipertenzijom; zatajenjem srca; kongestivnim zatajenjem srca; dijastoličkom ili sistoličkom disfunkcijom; koronarnom insuficijencijom; aritmijama; smanjenjem ventrikularnog predopterećenja; srčanom hipertrofijom; zatajenjem srca / kardiorenalnim sindromom; portalnom hipertenzijom; endotelnom disfunkcijom ili ozljedom;
• tromboemboličkim poremećajima i ishemijama; infarktom miokarda; moždanim udarom; prolaznim ishemijskim napadima (TIA); opstruktivnim tromboanginitisom; stabilnom ili nestabilnom anginom pektoris; koronarnim grčevima; varijantnom anginom; Prinzmetalovom anginom; restenozom koja je posljedica terapija trombolizom; trombogenim poremećajima;
• Alzheimerovom bolesti; Parkinsonovom bolesti; demencijom; vaskularnim kognitivnim oštećenjem; cerebralnim vazospazmom; traumatičnom ozljedom mozga;
• perifernom arterijskom bolesti; perifernom okluzivnom arterijskom bolesti; perifernom vaskularnom bolesti; hipertonijama; Raynaudovim sindromom ili fenomenom; kritičnom ishemijom ekstremiteta; vaskulitisom; perifernom embolijom; povremenim klaudiranjem; vazookluzivnom krizom; Ducheneovom mišićnom distrofijom; Beckerovom mišićnom distrofijom; abnormalnostima mikrocirkulacije; vaskularnim curenjem ili problemima s propusnosti;
• šokom; sepsom; kardiogenim šokom; kontrolom aktivacije leukocita; inhibicijom ili modulacijom agregacije trombocita;
• plućnim/respiratornom stanjima; plućnom hipertenzijom; plućnom arterijskom hipertenzijom i povezanom plućnom vaskularnom pregradnjom; lokaliziranom trombozom i hipertrofijom desnog dijela srca; plućnom hipertonijom; primarnom plućnom hipertenzijom; sekundarnom plućnom hipertenzijom; obiteljskom plućnom hipertenzijom; sporadičnom plućnom hipertenzijom, prekapilarnom plućnom hipertenzijom; idiopatskom plućnom hipertenzijom; trombotskom plućnom arteriopatijom; pleksogenom plućnom arteriopatijom; cističnom fibrozom; bronhokonstrikcijom ili plućnom bronhokonstrikcijom; akutnim respiratornim distres sindromom; plućnom fibrozom; transplantacijom pluća;
• plućnom hipertenzijom povezanom s disfunkcijom lijeve klijetke, hipoksemijom, hipertenzijama skupine I, II, III, IV i V SZO-a, bolestima mitralnog zaliska, konstriktivnim perikarditisom, aortnom stenozom, kardiomiopatijom, medijastinalnom fibrozom, plućnom fibrozom, anomalnom plućnom venskom drenažom, plućnom venookluzivnom bolesti, plućnim vaskulitisom, vaskularnom bolesti kolagena, kongenitalnom bolesti srca, plućnom venskom hipertenzijom, intersticijskom bolesti pluća, poremećajem disanja tijekom spavanja, apnejom za vrijeme spavanja, poremećajima alveolarne hipoventilacije, kroničnom izloženosti velikoj nadmorskoj visini, neonatalnom bolesti pluća, alveolarno-kapilarnom displazijom, bolesti srpastih stanica; poremećajima koagulacije; kroničnom tromboembolijom, plućnom embolijom zbog tumora, parazita ili stranog materijala, bolesti vezivnog tkiva, lupusom, šistosomijazom, sarkoidozom, kroničnom opstruktivnom bolesti pluća, astmom, emfizemom, kroničnim bronhitisom, hemangiomatozom plućne kapilare; histiocitozom X, limfangiomatozom i komprimiranim plućnim žilama zbog adenopatije, tumorom ili fibrozirajućim medijastinitisom;
• aterosklerotskim bolestima ili stanjima; aterosklerozom; aterosklerozom povezanom s endotelnom ozljedom, adhezijom i agregacijom trombocita i monocita, proliferacijom i migracijom glatkih mišića; restenozom; restenozom razvijenom nakon terapije trombolizom, perkutanih transluminalnih angioplastika (PTA), perkutanih transluminalnih koronarnih angioplastika (PTCA) i premosnice; upalom;
• kardiovaskularnom bolesti povezanom s metaboličkim sindromom, pretilošću, dislipidemijom, dijabetesom, visokim krvnim tlakom; poremećajima povezanima s lipidima kao što su dislipidemija, hiperkolesterolemija, hipertrigliceridemija, sitosterolemija, masna bolest jetre i hepatitis; preeklampsijom; napredovanjem policistične bolesti bubrega; nakupljanjem potkožnog masnog tkiva;
• cirozom jetre; cirozom jetre povezanom s kroničnom bolesti jetre; hepatičnom fibrozom, aktivacijom jetrenih zvjezdanih stanica, fibroznim kolagenom jetre; ukupnom akumulacijom kolagena; bolesti jetro nekro-upalnog i/ili imunološkog porijekla;
• poremećajima urogenitalnog sustava; bubrežnom fibrozom; kroničnom bolesti bubrega; zatajenjem bubrega koje je posljedica kroničnih bubrežnih bolesti ili insuficijencije; zatajenjem bubrega zbog akumulacije/taloženja i ozljede tkiva, progresivnom sklerozom i glomerulonefritisom; hipertrofijom prostate;
• sistemskom sklerozom;
• srčanom intersticijskom fibrozom; srčanom pregradnjom i fibrozom; srčanom hipertrofijom;
(2) ishemijom, reperfuzijskim oštećenjem; ishemijom/reperfuzijom povezanom s transplantacijom organa, transplantacijom pluća, plućnom transplantacijom ili srčanom transplantacijom; očuvanjem nadomjestaka krvi u bolesnika s traumom;
(3) seksualnim, ginekološkim i urološkim poremećajima odabranim među erektilnom disfunkcijom; impotencijom; preuranjenom ejakulacijom; ženskom seksualnom disfunkcijom; disfunkcijom ženskog seksualnog uzbuđenja; hipoaktivnim poremećajem seksualnog uzbuđenja; vaginalnom atrofijom; dispareunijom; atrofičnim vaginitisom; benignom hiperplazijom prostate (BPP) ili hipertrofijom ili povećanjem; opstrukcijom izlaza mjehura; sindromom bolnog mjehura (BPS); intersticijskim cistitisom (IC); preaktivnim mjehurom, neurogenim mjehurom i inkontinencijom; dijabetičkom nefropatijom;
(4) očnim bolestima ili poremećajima odabrani među glaukomom, retinopatijom, dijabetičkom retinopatijom, blefaritisom, sindromom suhog oka, Sjögrenovim sindromom;
(5) bolestima ili poremećajima sluha odabrani među oštećenjima sluha; djelomičnim ili potpunim gubitkom sluha; djelomičnom ili potpunom gluhoćom; zujanjem u ušima; gubitkom sluha uzrokovano bukom;
(6) topičkim ili kožnim poremećajima ili stanjima odabranim među dermalnom fibrozom, sklerodermijom, fibrozom kože;
(7) zacjeljivanjem rana; zacjeljivanjem rana u dijabetičara; poboljšanjem mikrovaskularne perfuzije; poboljšanjem mikrovaskularne perfuzije nakon ozljede kako bi se suzbio upalni odgovor u perioperativnoj njezi; analnim fisurama; dijabetičkim ulkusima; i
(8) drugim bolestima ili stanjima odabranim među metastazom raka; osteoporozom, gastroparezom; funkcionalnom dispepsijom; dijabetičkim komplikacijama; bolestima povezanima s endotelnom disfunkcijom; i neurološkim poremećajima povezanima sa smanjenom proizvodnjom dušičnog oksida.
4. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 3, pri čemu je bolest, zdravstveno stanje ili poremećaj infarkt miokarda, stabilna ili nestabilna angina pektoris; koronarni grčevi; varijantna angina ili Prinzmetalova angina.
5. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 3, pri čemu je bolest, zdravstveno stanje ili poremećaj odabran među arterijskom hipertenzijom, plućnom hipertenzijom, plućnom arterijskom hipertenzijom, rezistentnom hipertenzijom, dijabetičkom hipertenzijom i portalnom hipertenzijom.
6. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 3, pri čemu je bolest, zdravstveno stanje ili poremećaj odabran među bubrežnom fibrozom, zatajenjem bubrega koje je posljedica kroničnih bubrežnih bolesti ili insuficijencije, kroničnom bolesti bubrega, zatajenjem bubrega zbog akumulacije/taloženja i ozljede tkiva, progresivnom sklerozom i glomerulonefritisom i napredovanjem policistične bolesti bubrega.
7. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 3, pri čemu je bolest, zdravstveno stanje ili poremećaj dijabetička nefropatija.
8. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 3, pri čemu je bolest, zdravstveno stanje ili poremećaj retinopatija ili dijabetička retinopatija.
9. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 3, pri čemu je bolest, zdravstveno stanje ili poremećaj odabran među zatajenjem srca, kongestivnim zatajenjem srca, hipertrofijom desnog dijela srca, dijastoličkom disfunkcijom, sistoličkom disfunkcijom, zatajenjem srca / kardiorenalnim sindromom, koronarnom insuficijencijom, aritmijama, smanjenjem ventrikularnog predopterećenja i srčanom hipertrofijom.
10. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 9, pri čemu je bolest zatajenje srca.
11. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 9, pri čemu je bolest dijastolička disfunkcija.
12. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 9, pri čemu je bolest zatajenje srca / kardiorenalni sindrom.
13. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 9, pri čemu je bolest srčana hipertrofija.
14. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 6, pri čemu je bolest bubrežna fibroza.
15. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 4, pri čemu je bolest zatajenje bubrega zbog akumulacije/taloženja i ozljede tkiva, progresivna skleroza, glomerulonefritis i napredovanje policistične bolesti bubrega.
16. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 3, pri čemu je bolest, zdravstveno stanje ili poremećaj vazookluzivna kriza.
17. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 3, pri čemu se bolest, zdravstveno stanje ili poremećaj odabire među plućnim/respiratornom stanjima; plućnom hipertenzijom; plućnom arterijskom hipertenzijom i povezanom plućnom vaskularnom pregradnjom; lokaliziranom trombozom i hipertrofijom desnog dijela srca; plućnom hipertonijom; primarnom plućnom hipertenzijom; sekundarnom plućnom hipertenzijom; obiteljskom plućnom hipertenzijom; sporadičnom plućnom hipertenzijom, prekapilarnom plućnom hipertenzijom; idiopatskom plućnom hipertenzijom; trombotskom plućnom arteriopatijom; pleksogenom plućnom arteriopatijom; cističnom fibrozom; bronhokonstrikcijom ili plućnom bronhokonstrikcijom; akutnim respiratornim distres sindromom; plućnom fibrozom; i transplantacijom pluća.
18. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 3, pri čemu se bolest, zdravstveno stanje ili poremećaj odabire među plućnom hipertenzijom povezanom s disfunkcijom lijeve klijetke, hipoksemijom, hipertenzijama skupine I, II, III, IV i V SZO-a, bolestima mitralnog zaliska, konstriktivnim perikarditisom, aortnom stenozom, kardiomiopatijom, medijastinalnom fibrozom, plućnom fibrozom, anomalnom plućnom venskom drenažom, plućnom venookluzivnom bolesti, plućnim vaskulitisom, vaskularnom bolesti kolagena, kongenitalnom bolesti srca, plućnom venskom hipertenzijom, intersticijskom bolesti pluća, poremećajem disanja tijekom spavanja, apnejom za vrijeme spavanja, poremećajima alveolarne hipoventilacije, kroničnom izloženosti velikoj nadmorskoj visini, neonatalnom bolesti pluća, alveolarno-kapilarnom displazijom, bolesti srpastih stanica; poremećajima koagulacije; kroničnom tromboembolijom, plućnom embolijom zbog tumora, parazita ili stranog materijala, bolesti vezivnog tkiva, lupusom, šistosomijazom, sarkoidozom, kroničnom opstruktivnom bolesti pluća, astmom, emfizemom, kroničnim bronhitisom, hemangiomatozom plućne kapilare; histiocitozom X, limfangiomatozom i komprimiranim plućnim žilama zbog adenopatije, tumorom ili fibrozirajućim medijastinitisom.
19. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 3, pri čemu je bolest, zdravstveno stanje ili poremećaj kardiovaskularna bolest povezana s metaboličkim sindromom, pretilost, dislipidemija, dijabetes, visoki krvni tlak; poremećaji povezani s lipidima, dislipidemija, hiperkolesterolemija, hipertrigliceridemija, sitosterolemija, masna bolest jetre i hepatitis; preeklampsija; ili nakupljanje potkožnog masnog tkiva.
20. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 3, pri čemu se bolest, zdravstveno stanje ili poremećaj odabire među cirozom jetre; cirozom jetre povezanom s kroničnom bolesti jetre; hepatičnom fibrozom, aktivacijom jetrenih zvjezdanih stanica i fibroznim kolagenom jetre.
21. Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 3, pri čemu se bolest, zdravstveno stanje ili poremećaj odabire među srčanom intersticijskom fibrozom, srčanom pregradnjom i fibrozom.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790637P | 2013-03-15 | 2013-03-15 | |
| US201361914915P | 2013-12-11 | 2013-12-11 | |
| PCT/US2014/028370 WO2014144100A2 (en) | 2013-03-15 | 2014-03-14 | Sgc stimulators |
| EP14718278.6A EP2970243B1 (en) | 2013-03-15 | 2014-03-14 | Sgc stimulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200276T1 true HRP20200276T1 (hr) | 2020-05-29 |
Family
ID=50513493
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220376TT HRP20220376T1 (hr) | 2013-03-15 | 2014-03-14 | Sgc stimulatori |
| HRP20200276TT HRP20200276T1 (hr) | 2013-03-15 | 2020-02-18 | Stimulatori sgc |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220376TT HRP20220376T1 (hr) | 2013-03-15 | 2014-03-14 | Sgc stimulatori |
Country Status (24)
| Country | Link |
|---|---|
| US (8) | US9481689B2 (hr) |
| EP (3) | EP2970243B1 (hr) |
| JP (5) | JP2016517432A (hr) |
| KR (3) | KR102362835B1 (hr) |
| CN (5) | CN109384778B (hr) |
| AU (4) | AU2014227862C1 (hr) |
| BR (1) | BR112015023349A2 (hr) |
| CA (1) | CA2907111C (hr) |
| CY (1) | CY1122919T1 (hr) |
| DK (2) | DK2970243T3 (hr) |
| EA (2) | EA033168B1 (hr) |
| ES (3) | ES2911276T3 (hr) |
| HK (2) | HK1213541A1 (hr) |
| HR (2) | HRP20220376T1 (hr) |
| HU (2) | HUE048543T2 (hr) |
| IL (4) | IL285564B1 (hr) |
| LT (2) | LT2970243T (hr) |
| ME (1) | ME03664B (hr) |
| MX (2) | MX361208B (hr) |
| PL (2) | PL3660013T3 (hr) |
| PT (2) | PT2970243T (hr) |
| RS (2) | RS63108B1 (hr) |
| SI (2) | SI3660013T1 (hr) |
| WO (1) | WO2014144100A2 (hr) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4331610B2 (ja) | 2001-12-20 | 2009-09-16 | トリバスキュラー２，インコーポレイティド | 先進の血管内移植片 |
| CA2822381C (en) | 2010-12-23 | 2019-04-02 | Foundry Newco Xii, Inc. | System for mitral valve repair and replacement |
| WO2012177942A2 (en) | 2011-06-21 | 2012-12-27 | Hanson Gifford, Iii | Prosthetic heart valve devices and associated systems and methods |
| US9039757B2 (en) | 2011-10-19 | 2015-05-26 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
| US10016271B2 (en) | 2011-10-19 | 2018-07-10 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
| US9763780B2 (en) | 2011-10-19 | 2017-09-19 | Twelve, Inc. | Devices, systems and methods for heart valve replacement |
| EP4252714A3 (en) | 2011-10-19 | 2023-12-20 | Twelve, Inc. | Device for heart valve replacement |
| US9655722B2 (en) | 2011-10-19 | 2017-05-23 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
| US11202704B2 (en) | 2011-10-19 | 2021-12-21 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
| WO2013101830A1 (en) * | 2011-12-27 | 2013-07-04 | Ironwood Pharmaceuticals, Inc. | 2 - benzyl, 3 - (pyrimidin- 2 -yl) substituted pyrazoles useful as sgc stimulators |
| US9579198B2 (en) | 2012-03-01 | 2017-02-28 | Twelve, Inc. | Hydraulic delivery systems for prosthetic heart valve devices and associated methods |
| WO2014047325A1 (en) | 2012-09-19 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| ES2911276T3 (es) | 2013-03-15 | 2022-05-18 | Cyclerion Therapeutics Inc | Estimuladores de sGC |
| WO2014189974A1 (en) | 2013-05-20 | 2014-11-27 | Twelve, Inc. | Implantable heart valve devices, mitral valve repair devices and associated systems and methods |
| MX2016007522A (es) * | 2013-12-11 | 2017-12-15 | Ironwood Pharmaceuticals Inc | Estimuladores de guanilato ciclasa soluble (sgc). |
| EP3094327A1 (en) | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| MX2017003517A (es) * | 2014-09-17 | 2017-07-28 | Ironwood Pharmaceuticals Inc | Estimuladores de guanilato ciclasa soluble (sgc). |
| WO2016044446A2 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| JP6624616B2 (ja) * | 2014-09-17 | 2019-12-25 | サイクレリオン・セラピューティクス，インコーポレーテッド | ｓＧＣ刺激剤 |
| US20170298055A1 (en) * | 2014-09-17 | 2017-10-19 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| JP6896619B2 (ja) | 2014-10-06 | 2021-06-30 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーター |
| ES2839248T5 (es) | 2015-07-23 | 2024-02-22 | Bayer Pharma AG | Estimuladores y/o activadores de la guanilatociclasa soluble (sGC) en combinación con un inhibidor de la endopeptidasa neutra (inhibidor de NEP) y/o un antagonista de angiotensina AII y su uso |
| WO2017035002A1 (en) | 2015-08-21 | 2017-03-02 | Twelve Inc. | Implantable heart valve devices, mitral valve repair devices and associated systems and methods |
| EP3383372B1 (en) | 2015-11-30 | 2023-11-01 | Cyclerion Therapeutics, Inc. | Solid dispersions comprising a sgc stimulator |
| CN108463224A (zh) * | 2015-12-14 | 2018-08-28 | 铁木医药有限公司 | sGC刺激剂用于胃肠功能障碍治疗的应用 |
| WO2017122754A1 (ja) | 2016-01-12 | 2017-07-20 | 日本ケミファ株式会社 | 電位依存性ｔ型カルシウムチャネル阻害剤 |
| AU2017216429B2 (en) * | 2016-02-01 | 2022-10-06 | Cyclerion Therapeutics, Inc. | Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH) |
| WO2017173274A1 (en) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN105753783B (zh) * | 2016-04-08 | 2017-12-15 | 李文淏 | 一种合成塞来昔布的方法 |
| EP3448316B1 (en) | 2016-04-29 | 2023-03-29 | Medtronic Vascular Inc. | Prosthetic heart valve devices with tethered anchors |
| KR102513343B1 (ko) * | 2016-07-07 | 2023-03-22 | 사이클리온 테라퓨틱스, 인크. | sGC 자극제의 인 전구약물 |
| AU2017292811B2 (en) | 2016-07-07 | 2021-10-21 | Cyclerion Therapeutics, Inc. | Novel processes for preparation of soluble guanylate cyclase stimulators |
| KR20190025989A (ko) | 2016-07-07 | 2019-03-12 | 아이언우드 파마슈티컬스, 인코포레이티드 | sGC 자극제의 고체 형태 |
| CN109563077A (zh) | 2016-07-07 | 2019-04-02 | 铁木医药有限公司 | 用于制备可溶性鸟苷酸环化酶刺激剂的新方法 |
| EP3872080B1 (en) | 2016-09-02 | 2023-08-16 | Cyclerion Therapeutics, Inc. | Fused bicyclic sgc stimulators |
| EA038096B1 (ru) * | 2016-09-23 | 2021-07-06 | Сайклерион Терапьютикс, Инк. | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH) |
| BR112019006213A2 (pt) | 2016-09-30 | 2019-06-18 | Vertex Pharma | modulador de regulador de condutância transmembranar de fibrose cística, composições farmacêuticas, métodos de tratamento e processo para fazer o modulador |
| WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
| EP3525779A1 (de) | 2016-10-11 | 2019-08-21 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc stimulatoren und mineralocorticoid-rezeptor-antagonisten |
| CA3042713A1 (en) * | 2016-11-08 | 2018-05-17 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
| PT3551622T (pt) | 2016-12-09 | 2020-11-12 | Vertex Pharma | Modulador do regulador da condutância transmembrana da fibrose quística, composições farmacêuticas, métodos de tratamento e processo de fabrico do modulador |
| WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
| US10575950B2 (en) | 2017-04-18 | 2020-03-03 | Twelve, Inc. | Hydraulic systems for delivering prosthetic heart valve devices and associated methods |
| US10702378B2 (en) | 2017-04-18 | 2020-07-07 | Twelve, Inc. | Prosthetic heart valve device and associated systems and methods |
| US10433961B2 (en) | 2017-04-18 | 2019-10-08 | Twelve, Inc. | Delivery systems with tethers for prosthetic heart valve devices and associated methods |
| US10792151B2 (en) | 2017-05-11 | 2020-10-06 | Twelve, Inc. | Delivery systems for delivering prosthetic heart valve devices and associated methods |
| US10646338B2 (en) | 2017-06-02 | 2020-05-12 | Twelve, Inc. | Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods |
| US10709591B2 (en) | 2017-06-06 | 2020-07-14 | Twelve, Inc. | Crimping device and method for loading stents and prosthetic heart valves |
| BR112019025801A2 (pt) | 2017-06-08 | 2020-07-07 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| US10729541B2 (en) | 2017-07-06 | 2020-08-04 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
| US10786352B2 (en) | 2017-07-06 | 2020-09-29 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
| US11517564B2 (en) | 2017-07-17 | 2022-12-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| EP3661915B1 (en) | 2017-08-02 | 2022-03-09 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
| US11389449B2 (en) | 2017-09-14 | 2022-07-19 | Cyclerion Therapeutics, Inc. | Treatment of metabolic syndrome with an sGC stimulator |
| CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| KR20200097293A (ko) | 2017-12-08 | 2020-08-18 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| SG11202005718PA (en) * | 2017-12-19 | 2020-07-29 | Cyclerion Therapeutics Inc | Sgc stimulators |
| TW202402741A (zh) | 2018-01-10 | 2024-01-16 | 美商賽克瑞恩醫療公司 | 用於製備可溶性鳥苷酸環化酶刺激劑之新穎方法及中間物 |
| WO2019161534A1 (en) * | 2018-02-22 | 2019-08-29 | Ironwood Pharmaceuticals, Inc. | Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators |
| CN108129387B (zh) * | 2018-01-31 | 2020-05-22 | 南京药石科技股份有限公司 | 一种合成2-氮杂二环[4．1．0]庚烷-1-甲酸盐酸盐的制备方法 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| EP3787610A1 (en) | 2018-04-30 | 2021-03-10 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| BR112021000358A2 (pt) | 2018-07-11 | 2021-04-06 | Cyclerion Therapeutics, Inc. | Uso de estimulantes de sgc para o tratamento de distúrbios mitocondriais |
| JP2022514517A (ja) * | 2018-12-13 | 2022-02-14 | エヌエックスティー バイオメディカル，エルエルシー | 血液酸素化治療方法および装置 |
| EP3911675A1 (en) | 2019-01-17 | 2021-11-24 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| BR102019016950A2 (pt) * | 2019-08-15 | 2021-02-23 | Inst De Pesquisa Ensino Ciencia E Tecnologia Aplicada Inst Galzu | forma de dosagem intrauretral de medicamento; e dispositivo |
| WO2021167458A1 (en) | 2020-02-21 | 2021-08-26 | Universiteit Maastricht | Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme |
| CA3170508A1 (en) | 2020-02-26 | 2021-09-02 | Universiteit Maastricht | Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia |
| CN111440315B (zh) * | 2020-04-28 | 2021-07-02 | 中国科学院长春应用化学研究所 | 一种自修复热塑性聚脲弹性体及其制备方法 |
| CN112142716B (zh) * | 2020-10-29 | 2021-08-31 | 山东新时代药业有限公司 | 一种5元杂芳基取代的吡嗪衍生物及其应用 |
| CN112569179B (zh) * | 2020-12-25 | 2022-12-27 | 上海交通大学医学院附属第九人民医院 | 一种可注射水凝胶体系及其制备方法 |
| CN114957087A (zh) * | 2022-04-13 | 2022-08-30 | 湖南复瑞生物医药技术有限责任公司 | 一种帕罗韦德中间体制备方法 |
| CN117582909B (zh) * | 2024-01-19 | 2024-04-02 | 天津凯莱英医药科技发展有限公司 | 一种连续生产5-单硝酸异山梨酯的***和方法 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
| US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| DE3660408D1 (en) | 1985-02-27 | 1988-08-25 | Oerlikon Buehrle Ag | Apparatus for measuring the vibrations of a spiral bevel gear transmission in a gear-testing machine |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
| US5721365A (en) | 1989-09-15 | 1998-02-24 | Us Health | N-substituted piperazine NONOates |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5155137A (en) | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
| ES2112332T3 (es) | 1991-09-24 | 1998-04-01 | Us Health | Derivados de substitucion de oxigeno de productos de adicion de nucleofilo-oxido nitrico utilizados como promedicamentos donadores de oxido nitrico. |
| DE69131206T2 (de) | 1991-12-05 | 2000-01-05 | Wallac Oy | Lumineszierende lanthanidenchelate |
| US5814666A (en) | 1992-04-13 | 1998-09-29 | The United States As Represented By The Department Of Health And Human Services | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
| US5405919A (en) | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
| US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
| US5632981A (en) | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| US5691423A (en) | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| EP0722320B1 (en) | 1993-10-08 | 2000-07-19 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Use of nitric oxide-releasing compounds as medicaments for hypoxic cell radiation sensitization |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| US5700830A (en) | 1994-11-22 | 1997-12-23 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents for reducing metastasis risk |
| US5470862A (en) * | 1995-02-03 | 1995-11-28 | Ohmeda Pharmaceutical Products Division Inc. | Substituted pyrazolyl compounds and methods employing such compounds |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| EA000987B1 (ru) | 1995-06-21 | 2000-08-28 | Сионоги Энд Ко., Лтд. | Бициклические аминопроизводные и содержащие их антагонисты pgd2 |
| US5714511A (en) | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| EP0945450B1 (en) | 1996-12-12 | 2005-05-11 | Shionogi & Co., Ltd. | Fused heterocyclic benzenecarboxylic acid amide derivatives and pgd2 antagonists containing the same |
| BR9714016A (pt) | 1996-12-13 | 2000-02-29 | Shionogi & Co | Derivados de benzotiofenocarboxamida e antagonistas a pgd2, que compreendem os mesmos |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| ES2251200T3 (es) | 1998-07-08 | 2006-04-16 | Sanofi-Aventis Deutschland Gmbh | N-arilamidas del acido sulfonilaminocarboxilico sustituidas con azufre, su uso y preparaciones farmaceuticas que las comprenden. |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| CN1161101C (zh) | 1998-12-17 | 2004-08-11 | 阿尔扎有限公司 | 用多层包衣将填充液体的明胶胶囊转变成控制释放的*** |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| WO2003022814A1 (fr) | 2001-09-07 | 2003-03-20 | Ono Pharmaceutical Co., Ltd. | Derives d'indole |
| WO2001078697A2 (en) | 2000-04-12 | 2001-10-25 | Merck Frosst Canada & Co. | Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists |
| US20010051624A1 (en) | 2000-04-12 | 2001-12-13 | Jones Thomas R. | Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists |
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| AR031176A1 (es) * | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| TWI241190B (en) | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
| PE20020856A1 (es) | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
| PE20020870A1 (es) | 2001-02-13 | 2002-11-18 | Aventis Pharma Gmbh | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| US6511911B1 (en) | 2001-04-03 | 2003-01-28 | Advanced Micro Devices, Inc. | Metal gate stack with etch stop layer |
| WO2003022813A1 (fr) | 2001-09-07 | 2003-03-20 | Ono Pharmaceutical Co., Ltd. | Derives indole, methode de fabrication et medicaments renfermant lesdits derives en tant que principe actif |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| JPWO2003097042A1 (ja) | 2002-05-16 | 2005-09-15 | 塩野義製薬株式会社 | Ｐｇｄ２受容体拮抗剤 |
| JP4484108B2 (ja) | 2002-05-16 | 2010-06-16 | 塩野義製薬株式会社 | Ｐｇｄ２受容体拮抗作用を有する化合物 |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| DE10244810A1 (de) * | 2002-09-26 | 2004-04-08 | Bayer Ag | Neue Morpholin-überbrückte Indazolderivate |
| JP2006508077A (ja) | 2002-10-04 | 2006-03-09 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト |
| EA011087B1 (ru) | 2002-12-20 | 2008-12-30 | Эмджен Инк. | Соединения и фармацевтические композиции для лечения воспалительных заболеваний |
| CN100439371C (zh) * | 2003-04-29 | 2008-12-03 | 辉瑞大药厂 | 可用于治疗高血压的5,7-二氨基吡唑并[4,3-d]嘧啶 |
| EP1479679A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Triazole-derivatives as factor Xa inhibitors |
| CN1863511A (zh) | 2003-08-04 | 2006-11-15 | 辉瑞产品公司 | 提供控制释放的胆固醇酯转移蛋白抑制剂以及立即释放的HMG－CoA还原酶抑制剂的剂型 |
| US8309608B2 (en) | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
| WO2008124505A2 (en) | 2007-04-05 | 2008-10-16 | Ironwood Pharmaceuticals,Inc. | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders |
| EP2197551B1 (en) | 2007-09-06 | 2016-12-28 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CA2711134A1 (en) | 2008-01-24 | 2009-07-30 | Merck Sharp & Dohme Corp. | Angiotensin ii receptor antagonists |
| RU2010150451A (ru) * | 2008-05-10 | 2012-06-20 | Байер Шеринг Фарма Акциенгезельшафт (DE) | Стимуляторы ргц и их комбинации для лечения нарушения слуха |
| JP5501369B2 (ja) | 2008-11-25 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | 可溶性グアニレートシクラーゼ活性化剤 |
| KR20110133034A (ko) | 2009-02-26 | 2011-12-09 | 머크 샤프 앤드 돔 코포레이션 | 가용성 구아닐레이트 시클라제 활성화제 |
| WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| EP2549875B1 (en) | 2010-03-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| JP5708644B2 (ja) | 2010-04-27 | 2015-04-30 | 日本電気株式会社 | 情報処理端末およびその制御方法 |
| UA107112C2 (en) | 2010-05-27 | 2014-11-25 | Мерк Шарп Енд Доме Корп. | Activator of soluble guanylate cyclase |
| DK2588465T3 (en) | 2010-06-30 | 2017-05-01 | Ironwood Pharmaceuticals Inc | SGC stimulators |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| JP5878546B2 (ja) * | 2010-11-09 | 2016-03-08 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | ｓＧＣ刺激剤 |
| JP5976778B2 (ja) * | 2011-04-11 | 2016-08-24 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体 |
| CN104125957B (zh) | 2011-12-21 | 2016-05-25 | 拜耳知识产权有限责任公司 | 取代的苄基吡唑 |
| WO2013101830A1 (en) * | 2011-12-27 | 2013-07-04 | Ironwood Pharmaceuticals, Inc. | 2 - benzyl, 3 - (pyrimidin- 2 -yl) substituted pyrazoles useful as sgc stimulators |
| DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
| WO2014047111A1 (en) * | 2012-09-18 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| WO2014047325A1 (en) | 2012-09-19 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| ES2911276T3 (es) | 2013-03-15 | 2022-05-18 | Cyclerion Therapeutics Inc | Estimuladores de sGC |
| MX2016007522A (es) | 2013-12-11 | 2017-12-15 | Ironwood Pharmaceuticals Inc | Estimuladores de guanilato ciclasa soluble (sgc). |
| EP3094327A1 (en) | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
-
2014
- 2014-03-14 ES ES19208775T patent/ES2911276T3/es active Active
- 2014-03-14 LT LTEP14718278.6T patent/LT2970243T/lt unknown
- 2014-03-14 LT LTEP19208775.7T patent/LT3660013T/lt unknown
- 2014-03-14 RS RS20220352A patent/RS63108B1/sr unknown
- 2014-03-14 PT PT147182786T patent/PT2970243T/pt unknown
- 2014-03-14 IL IL285564A patent/IL285564B1/en unknown
- 2014-03-14 EP EP14718278.6A patent/EP2970243B1/en active Active
- 2014-03-14 CN CN201811216402.XA patent/CN109384778B/zh active Active
- 2014-03-14 EA EA201890641A patent/EA033168B1/ru unknown
- 2014-03-14 PL PL19208775T patent/PL3660013T3/pl unknown
- 2014-03-14 SI SI201431948T patent/SI3660013T1/sl unknown
- 2014-03-14 DK DK14718278.6T patent/DK2970243T3/da active
- 2014-03-14 ME MEP-2020-40A patent/ME03664B/me unknown
- 2014-03-14 HU HUE14718278A patent/HUE048543T2/hu unknown
- 2014-03-14 SI SI201431503T patent/SI2970243T1/sl unknown
- 2014-03-14 US US14/775,954 patent/US9481689B2/en active Active
- 2014-03-14 HU HUE19208775A patent/HUE059178T2/hu unknown
- 2014-03-14 CN CN201810569286.3A patent/CN108912111B/zh active Active
- 2014-03-14 KR KR1020217004630A patent/KR102362835B1/ko active IP Right Grant
- 2014-03-14 ES ES21214096T patent/ES2966517T3/es active Active
- 2014-03-14 KR KR1020157029189A patent/KR102218771B1/ko active IP Right Grant
- 2014-03-14 BR BR112015023349A patent/BR112015023349A2/pt not_active Application Discontinuation
- 2014-03-14 AU AU2014227862A patent/AU2014227862C1/en active Active
- 2014-03-14 DK DK19208775.7T patent/DK3660013T3/da active
- 2014-03-14 EP EP19208775.7A patent/EP3660013B1/en active Active
- 2014-03-14 CA CA2907111A patent/CA2907111C/en active Active
- 2014-03-14 MX MX2015012473A patent/MX361208B/es active IP Right Grant
- 2014-03-14 ES ES14718278T patent/ES2774295T3/es active Active
- 2014-03-14 EP EP21214096.6A patent/EP3998260B1/en active Active
- 2014-03-14 RS RS20200218A patent/RS59981B1/sr unknown
- 2014-03-14 HR HRP20220376TT patent/HRP20220376T1/hr unknown
- 2014-03-14 JP JP2016502769A patent/JP2016517432A/ja active Pending
- 2014-03-14 CN CN201480027900.3A patent/CN105408328B/zh active Active
- 2014-03-14 CN CN201811217263.2A patent/CN109369635B/zh active Active
- 2014-03-14 CN CN201811217841.2A patent/CN110016020B/zh active Active
- 2014-03-14 PT PT192087757T patent/PT3660013T/pt unknown
- 2014-03-14 PL PL14718278T patent/PL2970243T3/pl unknown
- 2014-03-14 WO PCT/US2014/028370 patent/WO2014144100A2/en active Application Filing
- 2014-03-14 EA EA201591743A patent/EA031746B1/ru unknown
- 2014-03-14 KR KR1020227004444A patent/KR102502937B1/ko active IP Right Grant
-
2015
- 2015-09-11 MX MX2021008281A patent/MX2021008281A/es unknown
- 2015-09-16 IL IL24164115A patent/IL241641B/en active IP Right Grant
-
2016
- 2016-02-03 HK HK16101279.2A patent/HK1213541A1/zh unknown
- 2016-07-21 US US15/215,628 patent/US9586937B2/en active Active
- 2016-08-18 HK HK16109921.7A patent/HK1221723A1/zh unknown
- 2016-08-24 US US15/245,697 patent/US10183021B2/en active Active
-
2017
- 2017-01-16 US US15/406,994 patent/US20170137439A1/en not_active Abandoned
- 2017-01-16 US US15/406,959 patent/US10517874B2/en active Active
- 2017-04-14 JP JP2017080301A patent/JP6267385B2/ja active Active
- 2017-04-14 JP JP2017080300A patent/JP6267384B2/ja active Active
-
2018
- 2018-10-12 JP JP2018193191A patent/JP6709000B2/ja active Active
- 2018-11-02 US US16/178,771 patent/US10639308B2/en active Active
-
2019
- 2019-05-22 AU AU2019203606A patent/AU2019203606B9/en active Active
- 2019-11-14 IL IL270646A patent/IL270646B/en active IP Right Grant
-
2020
- 2020-02-18 HR HRP20200276TT patent/HRP20200276T1/hr unknown
- 2020-02-27 CY CY20201100188T patent/CY1122919T1/el unknown
- 2020-03-13 US US16/817,830 patent/US11207323B2/en active Active
- 2020-05-07 JP JP2020081703A patent/JP7072602B2/ja active Active
- 2020-12-23 IL IL279695A patent/IL279695B/en unknown
-
2021
- 2021-06-24 AU AU2021204292A patent/AU2021204292B2/en active Active
- 2021-12-20 US US17/556,213 patent/US20230106002A1/en active Pending
-
2023
- 2023-04-04 AU AU2023202058A patent/AU2023202058A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200276T1 (hr) | Stimulatori sgc | |
| JP2016540017A5 (hr) | ||
| US10213395B2 (en) | Toxic aldehyde related diseases and treatment | |
| HRP20211355T1 (hr) | Fuzionirani biciklični sgc stimulatori | |
| JP2012107046A5 (hr) | ||
| RU2010113970A (ru) | Применение пептида phpfhlfvy (ингибитора ренина) в качестве терапевтического средства | |
| JP2011509303A5 (hr) | ||
| JP2011520917A5 (hr) | ||
| KR20100096108A (ko) | 건성 점막 치료용 오스모라이트-함유 제제 | |
| HRP20110763T1 (hr) | Makrolidni konjugati s protuupalnom aktivnošću | |
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| CN113699696A (zh) | 一种采用便携电纺丝技术制备的多层功能化伤口敷料 | |
| JP2018524274A (ja) | １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法 | |
| JP2014520854A5 (hr) | ||
| CN106727320A (zh) | 一种用于修复鼻粘膜、降低过敏反应、抗炎作用的组合物 | |
| DE10114762A1 (de) | Verwendung von Cysteinprotease-Inhibitoren | |
| CN110526870A (zh) | 一种艾曲波帕的制备方法 | |
| WO2009094811A1 (fr) | Préparation d'un mélange acide de gelée royale et son application | |
| CN105560253A (zh) | 化合物雷公藤甲素在脉络膜新生血管中的应用 | |
| CN105412118B (zh) | 治疗急慢性呼吸困难的西药组合物及其制备方法 | |
| CN107648296A (zh) | 一种紫草提取物的制备方法 | |
| CN106496106B (zh) | 丙氨酸衍生物 | |
| JP2014508740A5 (hr) | ||
| CN106563057A (zh) | 一种鼻炎药膏 | |
| CN103599099B (zh) | 银杏内酯双层渗透泵控释片及制备方法 |